Psoriatic arthritis (PsA) is a chronic immune-mediated disease manifesting as joint inflammation with functional impairment associated with psoriasis. Recently, PsA has emerged as a systemic disease with several comorbidities, such as cardiovascular diseases and metabolic disorders. Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) directed against phosphodiesterase 4 (PDE4) with demonstrated efficacy and safety in PsA and psoriasis. We report the case of a patient with PsA manifesting as arthritis, dactylitis, mild psoriasis and a significantly reduced health-related quality of life (HRQoL). Treatment with apremilast in association with methotrexate led to a quick improvement of joint and skin involvement with a stable amelioration of HRQoL. Furthermore, we observed a persistent favorable shift of serum lipid profile. Our observations suggest that apremilast is effective in controlling mild skin and joint involvement, including dactylitis, and suggest a potentially advantageous metabolic effect in patients with PsA.
Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis : a Case Report / R. Gualtierotti, O. De Lucia. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 8:3(2019 Mar 22), pp. 398.1-398.10.
|Titolo:||Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis : a Case Report|
GUALTIEROTTI, ROBERTA (Corresponding)
|Parole Chiave:||psoriatic arthritis; psoriasis; apremilast; lipid profile; DMARD|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
Settore MED/09 - Medicina Interna
|Data di pubblicazione:||22-mar-2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3390/jcm8030398|
|Appare nelle tipologie:||01 - Articolo su periodico|